Video
Dr. Cookson summarizes key prostate cancer research from 2022 ASCO GU
Author(s):
Urology Times® Co–Editor in Chief Michael S. Cookson, MD, MMHC, recaps 5 presentations from the 2022 Genitourinary Cancers Symposium.
In this video, Michael S. Cookson, MD, MMHC, gives a recap of noteworthy prostate cancer abstracts presented at the 2022 ASCO Genitourinary Cancers Symposium. Cookson, a professor and the Donald D. Albers Endowed Chair in Urology at the University of Oklahoma Health Sciences Center in Oklahoma City, a co–editor in chief for Urology Times®.
The following 5 abstracts are summarized:
Abstract 11: PROpel: Phase III trial of olaparib (ola) and abiraterone (abi) versus placebo and abi as first-line (1L) therapy for patients (pts) with metastatic castration-resistant prostate cancer
Abstract 12: Phase 3 MAGNITUDE study: First results of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) as first-line therapy in patient (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination repair (HRR) gene alterations
Abstract 13: Overall survival with darolutamide versus placebo in combination with androgen-deprivation therapy and docetaxel for metastatic hormone-sensitive prostate cancer in the phase 3 ARASENS trial
Abstract 9: Detection rate of 18F-rhPSMA-7.3 PET in Patients with Suspected Prostate Cancer Recurrence: Results from a Phase 3, Prospective, Multicenter Study (SPOTLIGHT)
Abstract 15: A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naive, metastatic castration-resistant prostate cancer (CRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE
